|
ZNF585A expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.44089209850063E-16 |
| Normal-vs-Stage2 |
4.14989997921111E-09 |
| Normal-vs-Stage3 |
1.8952617253376E-12 |
| Normal-vs-Stage4 |
1.78224102143076E-12 |
| Stage1-vs-Stage2 |
9.131200E-01 |
| Stage1-vs-Stage3 |
9.301700E-02 |
| Stage1-vs-Stage4 |
2.175900E-02 |
| Stage2-vs-Stage3 |
2.812800E-01 |
| Stage2-vs-Stage4 |
1.188180E-01 |
| Stage3-vs-Stage4 |
4.825200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.11022302462516E-16 |
| Normal-vs-AfricanAmerican |
1.87214999999297E-05 |
| Normal-vs-Asian |
3.05120040344775E-10 |
| Caucasian-vs-AfricanAmerican |
3.257200E-01 |
| Caucasian-vs-Asian |
8.961000E-01 |
| AfricanAmerican-vs-Asian |
3.278400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.82054371578033E-12 |
| Normal-vs-Female |
1.62436730732907E-12 |
| Male-vs-Female |
1.244030E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.63702384980979E-12 |
| Normal-vs-Age(41-60Yrs) |
5.55111512312578E-16 |
| Normal-vs-Age(61-80Yrs) |
7.01327884655711E-13 |
| Normal-vs-Age(81-100Yrs) |
3.376000E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.127200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.982430E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.096200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.731200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.591200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.411600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.968300E-04 |
| Classical-VS-Follicular |
4.407800E-01 |
| Classical-VS-Other |
2.060600E-01 |
| Classical-VS-Normal |
6.06990013807263E-11 |
| Tall-VS-Follicular |
1.575990E-02 |
| Tall-VS-Other |
8.708400E-01 |
| Tall-VS-Normal |
1.64124269730337E-12 |
| Follicular-VS-Other |
3.846400E-01 |
| Follicular-VS-Normal |
1.5020984456271E-11 |
| Other-VS-Normal |
2.011400E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
3.98959754122075E-11 |
| N0-vs-N1 |
3.014200E-01 |
|
|
